Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-05-14 16:10:04 ET · period of report 2026-05-12 · accession 0000875320-26-000222 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-14 16:10 | 2026-05-12 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -6,988 | 26.1K | -21% | -$3.14M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-12 | S | D | 6,988 | $450.00 | 26,088 | D | — | — | (F1) Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. |